Head-to-head evidence
semaglutide vs VCT220
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
semaglutide · Wegovy / Ozempic / Rybelsus
Marketed by Novo Nordisk
NCT03548935 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial of 1,961 participants. At week 68, mean body-weight change was -15.6% with semaglutide versus -2.8% with placebo, and the primary comparison was statistically significant (p<0.0001), supporting strong evidence for this clinical weight-loss endpoint.
Next expected readout: October 2026 · NCT07505303 (registry estimate)
VCT220
Developed by Ji Xing Pharmaceuticals (CORXEL) under a licence from Vincentage Pharma
NCT06569355 · Phase 2 · completed
This Phase 2 trial randomly assigned 250 people with obesity or overweight to one of several VCT220 doses or placebo, with participants, carers, investigators and outcome assessors unaware of assignment. The primary measure was percentage change in body weight at week 16. Weight fell by between 5.8% and 9.7% across the VCT220 dose groups against 1.6% on placebo, with reductions of 9.7% and 9.4% at the two 160 mg schedules (p of 0.001 or lower).
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: semaglutide's landscape · VCT220's landscape